Aminosalicylic acid adverse reactions: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Aminosalicylic acid}} | {{Aminosalicylic acid}} | ||
{{CMG}} ; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
==Adverse Reactions== | |||
The most common side effect is gastrointestinal intolerance manifested by [[nausea]], [[vomiting]], [[diarrhea]], and [[abdominal pain]]. | |||
Hypersensitivity reactions: Fever, skin eruptions of various types, including [[exfoliative dermatitis]], [[infectious mononucleosis]]-like, or [[lymphoma]]-like syndrome, [[leucopenia]], [[agranulocytosis]], [[thrombocytopenia]], [[Coombs' positive hemolytic anemia]], [[jaundice]], [[hepatitis]], [[pericarditis]], [[hypoglycemia]], [[optic neuritis]], [[encephalopathy]], [[Loeffler syndrome]], [[vasculitis]] and a reduction in [[prothrombin]]. | |||
[[Crystalluria]] may be prevented by the maintenance of urine at a neutral or an alkaline pH.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PASER (AMINOSALICYLIC ACID) GRANULE, DELAYED RELEASE [JACOBUS PHARMACEUTICAL COMPANY, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f2753dc-5f0c-4f49-9335-e519afb69ba6 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
{{Reflist}} | {{Reflist}} | ||
Latest revision as of 22:23, 25 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Adverse Reactions
The most common side effect is gastrointestinal intolerance manifested by nausea, vomiting, diarrhea, and abdominal pain.
Hypersensitivity reactions: Fever, skin eruptions of various types, including exfoliative dermatitis, infectious mononucleosis-like, or lymphoma-like syndrome, leucopenia, agranulocytosis, thrombocytopenia, Coombs' positive hemolytic anemia, jaundice, hepatitis, pericarditis, hypoglycemia, optic neuritis, encephalopathy, Loeffler syndrome, vasculitis and a reduction in prothrombin.
Crystalluria may be prevented by the maintenance of urine at a neutral or an alkaline pH.[1]
References
Adapted from the FDA Package Insert.